Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.

Community Practice Connections™: How the Experts Approach Testing and Treatment When Utilizing PARP Inhibitors for mCRPC

Release Date: November 30, 2021
Expiration Date: November 30, 2022

Activity Overview

Testing for germline and somatic mutations in tumors from patients with metastatic castration-resistant prostate cancer (mCRPC) has revealed altered genes associated with DNA damage repair (DDR) mechanisms, including BRCA1/2, CHEK2, and ATM, in up to 12% of samples. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes play an important role in the DDR system by binding damaged DNA to recruit components necessary to repair DNA single-strand breaks. In cancer cells homozygous for mutations in BRCA1 or BRCA2 and, thus, deficient for DDR, susceptibility to PARP inhibitors could potentially avoid the toxic effects of chemotherapy and radiation.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the virtual Medical Crossfire^® symposium held on September 10, 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with prostate cancer and putting recent clinical trial data into context. The program is designed to inform those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward urologists, oncologists, and researchers interested in the treatment of prostate cancer. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with prostate cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the mechanistic rationale as well as testing recommendations for utilizing PARP inhibition in the clinic in patients with prostate cancer
Determine strategies to effectively integrate PARP inhibitors into the treatment of patients with mCRPC
Explain efficacy and safety data of currently approved PARP inhibitors for treatment of patients with mCRPC
Assess emerging evidence and ongoing trials that are evaluating PARP inhibitors as part of combination strategies in mCRPC management settings

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

Faculty

Neal Shore, MD, FACS
US Chief Medical Officer, Surgery and Oncology
GenesisCare USA
Director, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, SC

Disclosures: Consultant: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Clovis Oncology, CG Oncology, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, GenesisCare, lnvitae, Janssen, MDxHealth, Merck & Co., Myovant Sciences, Myriad Genetics, Nymox Pharmaceutical, Pacific Edge Diagnostics, Pfizer, Phosphorous Pharmaceuticals, Propella Therapeutics, PreView, Sanofi Genzyme, Specialty Networks, Sesen Bio, Tolmar, UroGen Pharma; Speakers Bureau: Astellas Pharma, AstraZeneca, Bayer, Clovis Oncology, Foundation Medicine, Guardant Health, Janssen, Merck & Co., Pfizer.

Robert Dreicer, MD, MS, MACP, FASCO
Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA

Disclosures: Grant/Research Support: Arvinas, Bristol Myers Squibb, Seagen; Consultant: Astellas Pharma, AstraZeneca, Bayer, Eisai, EMD Serono, Exelixis, Gilead Sciences, Hinova Pharmaceuticals, Infinity Pharmaceuticals, Janssen Pharmaceuticals, Merck & Co., Myovant Sciences, Pfizer, Propella Therapeutics, Tavanta Therapeutics, Veru Inc.

Celestia S. Higano, MD, FACP
Adjunct Professor, Department of Urologic Science
University of British Columbia
Medical Director, Prostate Cancer Supportive Care Program
Vancouver Prostate Centre
Vancouver, British Columbia, Canada

Disclosures: Grant/Research Support: Clovis Oncology, Pfizer; Consultant: AstraZeneca, Clovis Oncology, Merck & Co., Pfizer; Other: AstraZeneca IDMCs.

Daniel P. Petrylak, MD
Professor of Medical Oncology and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Co-Leader, Cancer Signaling Networks
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosures: Grant/Research Support: Advanced Accelerator Applications, Agensys, Astellas Pharma, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Eli Lilly and Company, Endocyte, Genentech, Gilead Sciences, Innocrin Pharmaceuticals, MedImmune, Medivation, Merck & Co., Mirati Therapeutics, Novartis, Pfizer, Progenics Pharmaceuticals, Replimune Group, Roche; Consultant: Advanced Accelerator Applications, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly and Company, Exelixis, Gilead Sciences, Incyte, Ipsen, Janssen, Mirati Therapeutics, Monopteros Therapeutics, Pfizer, Pharmacyclics, Regeneron Pharmaceuticals, Roche, Seagen, UroGen Pharma; Shareholder: Bellicum Pharmaceuticals (sold July 2020), Tyme Technologies (sold October 2019).

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.